{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444377257
| IUPAC_name = (4S)-3-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
| image = Imidapril structure.png
| tradename =
| Drugs.com =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number_Ref =
| CAS_number = 89371-37-9
| ATC_prefix = C09
| ATC_suffix = AA16
| ATC_supplemental =
| PubChem = 5464343
| DrugBank_Ref =
| DrugBank =
| UNII_Ref =
| UNII = BW7H1TJS22
| KEGG_Ref =
| KEGG = D08068
| ChemSpiderID_Ref =
| ChemSpiderID = 4576628
| ChEMBL_Ref =
| ChEMBL = 317094
| smiles = O=C(O)[C@H]2N(C(=O)C@@HOCC)CCc1ccccc1)C)C(=O)N(C)C2
| InChI = 1/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
| InChIKey = KLZWOWYOHUKJIG-BPUTZDHNBX
| StdInChI_Ref =
| StdInChI = 1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
| StdInChIKey_Ref =
| StdInChIKey = KLZWOWYOHUKJIG-BPUTZDHNSA-N
| chemical_formula =
| C=20 | H=27 | N=3 | O=6
| molecular_weight = 405.444 g/mol
}}
咪达普利（）商品名：达爽，是一款血管紧张素转化酶抑制剂抗高血压药物，在1993年由日本田边制药研制并投入市场。
咪达普利口服后，在体内转换成活性代谢物咪达普利拉（Imidaprilat）。咪达普利拉可抑制血管紧张素转化酶活性，阻止血管紧张素I向血管紧张素II的转化，使外周血管舒张，降低血管阻力，产生降压作用。成人服用量为每日5~10mg。
副作用
咪达普利不良反应有低血压、头痛、咽部不适、皮疹、咳嗽；偶有伴呼吸困难的血管神经性水肿、肝肾功能损害、血象异常。对服用其他ACEI曾引起血管神经性水肿的患者以及妊娠妇女禁用。
药物相互作用
药物配伍禁忌
- 葡萄糖硫酸纤维素吸附器进行LDL治疗
** 可能引起休克
- 丙烯酸腈甲烯丙基磺酸钠膜(AN69)进行血液透析
** 可能发生过敏症状
药物分类
- ATC：C09AA16
- 血管紧张素转换酶抑制剂
- 循环系统药物
参考资料
评论 (0)